Full-Time

Principal Scientist

Protein Analytics & Biophysics-Target Binding

Posted on 7/29/2024

Generate Biomedicines

Generate Biomedicines

201-500 employees

Generates novel medicines using generative biology

AI & Machine Learning
Biotechnology

Senior, Expert

Cambridge, MA, USA

Category
Lab & Research
Interdisciplinary Research
Life Sciences
Required Skills
Data Analysis
Requirements
  • PhD in a scientific field of study and 8+ years of relevant research experience, Master’s degree in a scientific field of study and 14 years of relevant research experience, or B.S. in a science-related discipline with 16+ years of relevant research experience. Industry experience is required
  • Deep expertise and extensive hands-on experience in biomolecular interaction analysis using biosensor-based platforms (Carterra LSA, Biacore, Octet) and solution-based approaches (KinExA, Gyrolab) is required
  • Highly skilled in experimental design with a strong ability to analyze, interpret and communicate complex kinetic and mechanistic data
Responsibilities
  • Drive the design and execution of fit-for-purpose binding assays and workflows using techniques such as surface plasmon resonance (SPR), bio-layer interferometry (BLI) and kinetic exclusion assay (KinExA) in alignment with program goals and with broader organizational objectives
  • Demonstrate a proven track record of efficiently collating, analyzing, visualizing, interpreting and communicating complex data sets using a repertoire of digital tools
  • Pioneer efforts to maximize productivity, streamline processes and expand machine learning capabilities by integrating new and innovative technologies
  • Collaborate with computational scientists and multidisciplinary project teams to support critical decision-making checkpoints throughout discovery process
  • Provide technical oversight and strategic guidance to functional team members
Generate Biomedicines

Generate Biomedicines

View

Generate Biomedicines focuses on creating new medicines by combining machine learning, biological engineering, and medicine. The company uses a method called generative biology, which involves analyzing millions of proteins to learn how nature encodes their functions. This knowledge allows them to design new medicines with specific therapeutic effects. Their main product, The Generate Platform, enables the rapid production of medicines across various therapeutic areas, making the drug discovery process more efficient compared to traditional methods. Unlike other companies in the biotechnology and pharmaceutical sectors, Generate Biomedicines emphasizes a proactive approach to medicine creation. Their goal is to democratize access to biotherapeutics, and they have already generated and tested 42,000 proteins, with plans for further expansion.

Company Stage

Series C

Total Funding

$674.1M

Headquarters

Somerville, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • Generative AI is enhancing Generate Biomedicines' drug discovery capabilities.
  • Strategic alliances, like with Novartis, leverage AI for drug development.
  • Samsung's investment indicates strong market confidence in Generate Biomedicines.

What critics are saying

  • Intellectual property disputes may arise as the generative biology platform expands.
  • Technological advancements may render current platforms obsolete without continuous innovation.
  • Reliance on partnerships could pose risks if collaborations don't meet expectations.

What makes Generate Biomedicines unique

  • Generate Biomedicines uses generative biology to create protein-based medicines efficiently.
  • The Generate Platform allows rapid production of medicines across multiple therapeutic areas.
  • The company integrates machine learning with biological engineering for innovative drug discovery.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE